Data-Driven Insights

July 12, 2019   |   Brandon Underwood

Cancellation Reasons Highlight the Opportunity to Proactively Support Stalled Patient Cases

The quality of status and sub-status data reported by SPs is an ongoing challenge that limits the actionability of data specialty brands have contracted to receive. Clearly, poor data quality limits the level of insights that analytics can surface for key stakeholders. Simply cleansing and stewarding Cancellation reasons unlocks tremendous value in understanding why patients are abandoning scripts.

Read More

Tags: , , , , , , ,


February 7, 2019   |   Brandon Underwood

Specialty Pharmacy Patient Status Data Quality Challenges and Solutions

Without visibility into each individual patient journey, your specialty brand cannot consistently intervene to help patients overcome barriers to therapy initiation and adherence. Today, the poor quality of specialty patient status data is making it impossible to calculate accurate KPI metrics and uncover true patient journey insights. This blog post examines in detail three critical patient status data quality challenges and recommends solutions your specialty brand can implement to overcome these challenges, and ultimately, help patients start therapy faster and stay on therapy longer.

Read More

Tags: , , , ,



December 10, 2018   |   Brandon Underwood

Five Steps to a Better Specialty Pharmacy Data Contracting Strategy

An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language, determine the metric outputs that are possible. This post looks at how the right specialty data contracting decisions enable diagnostic patient journey insights that help specialty brands save patient days of therapy.

Read More

Tags: , , , ,


September 26, 2018   |   Brandon Underwood

Frequently Asked Questions – 340B Program

The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities.

Read More

Tags: , , , , , , , , ,


August 20, 2018   |   Shivani Patel

Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring

The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny and need new approaches to monitor and report on irregular order patterns for controlled substances. This post discusses a new approach that provides visibility across pharmacy locations and wholesale distributors while weaving in additional demographic insights.

Read More

Tags: , , , , ,


August 3, 2018   |   Sean McCarthy

3 Key Opportunities to Improve Specialty Patient Initiation

Sean McCarthy

There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to First Fill and increase overall Fill Rate for new patient referrals. Each key opportunity to improve patient initiation is related to a friction point in the patient journey. In this post, IntegriChain Patient Access Segment Leader Sean McCarthy provides an overview of these key opportunities and the potential of analytics to unlock efficiencies for specialty brands.

Read More

Tags: , , , , , ,


July 27, 2018   |   David Carlson

The Economics of Rare Disease and Implications for Payer Contract Strategy

David Carlson

Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.

Read More

Tags: , , , , ,


March 21, 2017   |   Brandon Underwood

Specialty Pharmacy Status/Sub-Status Analysis Highlights Inconsistencies in Data Quality

Brandon Underwood offers a sneak peek at IntegriChain's upcoming Specialty Analytics benchmark report. IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory. Overall, IntegriChain and ProMetrics analyzed more than 657,000 sub-status records reported in Q4 2016. The brands we studied had comparable status/sub-status reporting requirements.

Read More

Tags: , , ,


June 2, 2016   |   Sunay Shah

Leveraging Scorecard Analytics to Optimize Changes to DSAs

In my last post, I explored how IntegriChain Scorecard Analytics can be used to validate whether the implementation of Distribution Service Agreements (DSAs) drives channel performance. In this post, we will deep dive with a step-by-step approach outlining how Scorecard Analytics can be leverage to optimize changes to DSAs. First, let’s look at the metrics. DSA metrics come in two basic flavors – performance and data transmission The performance metrics are typically composed of a service level metric, purchase stability (or demand variability) metric, and an inventory level metric. The data transmission metrics are typically composed of data delivery timeliness, completeness, and […]

Read More

Tags: , , ,


adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand